Phase 3 testing confirms HIV fat disorder drug findings
Posted on December 18, 2008
Filed Under 365Gay, News
(Montreal, Quebec) Theratechnologies has concluded a Phase 3 trial confirming earlier clinical results on the safety and effectiveness of its lead drug, tesamorelin, for an HIV-related fat disorder.
Patients lost 18 per cent of their excess visceral fat after 52 weeks of treatment, …
Tags: Disorder Patients, hiv, Lead, Lost, Montreal Quebec, Phase 3, Theratechnologies, Visceral FatComments
Leave a Reply
